Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16700146 | 0.98 | ACHE (0.61) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL3103642 | 0.93 | ACHE (0.53) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Cetylpyridinium SCHEMBL9738456 | 0.88 | ACHE (0.77) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Cetylpyridinium SCHEMBL9738452 | 0.88 | ACHE (0.77) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Trichloroacetic Acid SCHEMBL9784545 | 0.87 | ACHE (0.65) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Acetic Acid SCHEMBL30330818 | 0.86 | ACHE (0.74) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Acetic Acid SCHEMBL29252048 | 0.86 | ACHE (0.74) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Acetic Acid SCHEMBL30213001 | 0.86 | ACHE (0.74) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Acetic Acid SCHEMBL9358811 | 0.86 | ACHE (0.74) | ACHECHRM2ADRA2AADORA3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL16699833 | 0.86 | CHRM2 (0.42) | ACHECHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117524-B1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
| EP-2117524-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | National Research Council of Canada (CA) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092257-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-08-07 | — | — | WO | disclosed |
| WO-2005082860-A1 | TETRACYCLINES AND THEIR USE AS CALPAIN INHIBITORS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | ACHE 515/4885CHRM2 75/4885ADRA2A 10/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | ACHE 990/4885CHRM2 982/4885ADRA2A 28/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | ACHE 1106/4885CHRM2 228/4885ADRA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.